Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hematologic disorders in critically ill patients.

Kelly W Mercer1, B Gail Macik, Michael E Williams

  • 1Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA.

Seminars in Respiratory and Critical Care Medicine
|June 23, 2006
PubMed
Summary

Critically ill patients often develop thrombocytopenia (low platelet count) and coagulopathies. Prompt diagnosis and treatment, especially for heparin-induced thrombocytopenia (HIT), are crucial for managing these hematologic disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.

Leukemia·2026
Same author

Bridging the Gap: Pirtobrutinib for Treatment-Naïve Chronic Lymphatic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Targeting persister cells: proactively overcoming therapy resistance in aggressive B cell lymphomas.

Trends in cancer·2026
Same author

Optimizing mesenchymal stem cell therapy: from isolation to GMP-compliant expansion for clinical application.

BMC molecular and cell biology·2025
Same author

Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms.

Blood cancer journal·2023

Area of Science:

  • Critical Care Medicine
  • Hematology
  • Pharmacology

Background:

  • Hematologic disorders, including thrombocytopenia and coagulopathies, are prevalent in intensive care units (ICUs).
  • Thrombocytopenia in critically ill patients can lead to adverse outcomes and requires thorough evaluation.
  • Heparin-induced thrombocytopenia (HIT) poses a significant risk of thrombosis and necessitates prompt recognition.

Purpose of the Study:

  • To outline the systematic evaluation of hematologic disorders in critically ill patients.
  • To emphasize the importance of recognizing heparin-induced thrombocytopenia (HIT) and its management.
  • To discuss coagulopathies, including vitamin K deficiency and disseminated intravascular coagulation (DIC), and emerging treatments.

Main Methods:

  • Systematic evaluation of clinical and laboratory findings for thrombocytopenia.

Related Experiment Videos

  • Interpretation of clotting studies to define coagulation defects.
  • Review of current understanding and treatment approaches for DIC and novel hemostatic agents.

    • Main Results:

    • Thrombocytopenia is common in ICUs and requires careful diagnosis to guide therapy.
    • Heparin-induced thrombocytopenia (HIT) mandates immediate cessation of heparin and consideration of direct thrombin inhibitors.
    • Coagulopathies, such as vitamin K deficiency and DIC, are frequent, with new treatments like recombinant activated protein C showing promise.

    Conclusions:

    • Effective management of hematologic disorders in the ICU hinges on accurate diagnosis and timely intervention.
    • Prompt recognition and management of HIT are critical to prevent thrombotic complications.
    • Advances in understanding DIC and the use of agents like recombinant factor VIIa offer potential therapeutic strategies, though further data are needed for off-label uses.